Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes
Diamyd Medical has been granted a patent in Hong Kong protecting the use of insulin-based antigens to treat individuals with type 1 diabetes carrying the HLA DR4-DQ8 genetic marker. The patent is valid until 2038 and further strengthens the company’s global IP portfolio in precision medicine for type 1 diabetes.Diamyd Medical holds granted precision medicine patents for treating and preventing type 1 diabetes in key global markets: · Treatment and prevention of type 1 diabetes in individuals carrying HLA DR3-DQ2 using Diamyd[®] (GAD/alum) is granted in Europe, Eurasia, Hong Kong,